Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Amortization of Deferred Charges data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 68.38% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 168.38% increase from a year earlier, with the FY2025 full-year figure at $8.0 million, changed N/A from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $2.3 million, up from $1.3 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for SUPN reached as high as $2.3 million in Q1 2026 and fell as low as $500000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $888000.0 across 4 years, with a median of $530000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges slumped 88.37% in 2022 and soared 68.38% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $530000.0 in 2022, then grew by 0.38% to $532000.0 in 2023, then soared by 152.07% to $1.3 million in 2025, then surged by 68.38% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $2.3 million in Q1 2026, $1.3 million in Q1 2025, and $532000.0 in Q1 2023.